Matches in SemOpenAlex for { <https://semopenalex.org/work/W2164858045> ?p ?o ?g. }
- W2164858045 endingPage "460" @default.
- W2164858045 startingPage "451" @default.
- W2164858045 abstract "Background Rheumatoid arthritis is a heterogeneous chronic disease, and no therapeutic agent has been identified which is universally and persistently effective in all patients. We investigated the effectiveness of tofacitinib (CP-690,550), a novel oral Janus kinase inhibitor, as a targeted immunomodulator and disease-modifying therapy for rheumatoid arthritis. Methods We did a 6-month, double-blind, parallel-group phase 3 study at 82 centres in 13 countries, including North America, Europe, and Latin America. 399 patients aged 18 years or older with moderate-to-severe rheumatoid arthritis and inadequate response to tumour necrosis factor inhibitors (TNFi) were randomly assigned in a 2:2:1:1 ratio with an automated internet or telephone system to receive twice a day treatment with: tofacitinib 5 mg (n=133); tofacitinib 10 mg (n=134); or placebo (n=132), all with methotrexate. At month 3, patients given placebo advanced to either tofacitinib 5 mg twice a day (n=66) or 10 mg twice a day (n=66). Primary endpoints included American College of Rheumatology (ACR)20 response rate, mean change from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI), and rates of disease activity score (DAS)28-4(ESR) less than 2·6 (referred to as DAS28<2·6), all at month 3. The full analysis set for the primary analysis included all randomised patients who received at least one dose of study medication and had at least one post-baseline assessment. This trial is registered with www.ClinicalTrials.gov, number NCT00960440. Findings At month 3, ACR20 response rates were 41·7% (55 of 132 [95% CI vs placebo 6·06–28·41]; p=0·0024) for tofacitinib 5 mg twice a day and 48·1% (64 of 133; [12·45–34·92]; p<0·0001) for tofacitinib 10 mg twice a day versus 24·4% (32 of 131) for placebo. Improvements from baseline in HAQ-DI were −0·43 ([−0·36 to −0·15]; p<0·0001) for 5 mg twice a day and −0·46 ([−0·38 to −0·17]; p<0·0001) for 10 mg twice a day tofacitinib versus −0·18 for placebo; DAS28<2·6 rates were 6·7% (eight of 119; [0–10·10]; p=0·0496) for 5 mg twice a day tofacitinib and 8·8% (11 of 125 [1·66–12·60]; p=0·0105) for 10 mg twice a day tofacitinib versus 1·7% (two of 120) for placebo. Safety was consistent with phase 2 and 3 studies. The most common adverse events in months 0–3 were diarrhoea (13 of 267; 4·9%), nasopharyngitis (11 of 267; 4·1%), headache (11 of 267; 4·1%), and urinary tract infection (eight of 267; 3·0%) across tofacitinib groups, and nausea (nine of 132; 6·8%) in the placebo group. Interpretation In this treatment-refractory population, tofacitinib with methotrexate had rapid and clinically meaningful improvements in signs and symptoms of rheumatoid arthritis and physical function over 6 months with manageable safety. Tofacitinib could provide an effective treatment option in patients with an inadequate response to TNFi. Funding Pfizer." @default.
- W2164858045 created "2016-06-24" @default.
- W2164858045 creator A5003335288 @default.
- W2164858045 creator A5005113837 @default.
- W2164858045 creator A5027269428 @default.
- W2164858045 creator A5029796262 @default.
- W2164858045 creator A5031531166 @default.
- W2164858045 creator A5035639364 @default.
- W2164858045 creator A5040449706 @default.
- W2164858045 creator A5053704561 @default.
- W2164858045 creator A5062789852 @default.
- W2164858045 creator A5064863811 @default.
- W2164858045 creator A5067393049 @default.
- W2164858045 creator A5071102167 @default.
- W2164858045 creator A5076851275 @default.
- W2164858045 creator A5080399165 @default.
- W2164858045 date "2013-02-01" @default.
- W2164858045 modified "2023-10-11" @default.
- W2164858045 title "Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial" @default.
- W2164858045 cites W2024644107 @default.
- W2164858045 cites W2038962823 @default.
- W2164858045 cites W2046628605 @default.
- W2164858045 cites W2081734937 @default.
- W2164858045 cites W2101217991 @default.
- W2164858045 cites W2108271686 @default.
- W2164858045 cites W2110177517 @default.
- W2164858045 cites W2114308202 @default.
- W2164858045 cites W2116843833 @default.
- W2164858045 cites W2124670599 @default.
- W2164858045 cites W2140965629 @default.
- W2164858045 cites W2155109530 @default.
- W2164858045 cites W2159106700 @default.
- W2164858045 cites W2166732840 @default.
- W2164858045 cites W2319957449 @default.
- W2164858045 cites W4210968471 @default.
- W2164858045 cites W4249063051 @default.
- W2164858045 doi "https://doi.org/10.1016/s0140-6736(12)61424-x" @default.
- W2164858045 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23294500" @default.
- W2164858045 hasPublicationYear "2013" @default.
- W2164858045 type Work @default.
- W2164858045 sameAs 2164858045 @default.
- W2164858045 citedByCount "569" @default.
- W2164858045 countsByYear W21648580452012 @default.
- W2164858045 countsByYear W21648580452013 @default.
- W2164858045 countsByYear W21648580452014 @default.
- W2164858045 countsByYear W21648580452015 @default.
- W2164858045 countsByYear W21648580452016 @default.
- W2164858045 countsByYear W21648580452017 @default.
- W2164858045 countsByYear W21648580452018 @default.
- W2164858045 countsByYear W21648580452019 @default.
- W2164858045 countsByYear W21648580452020 @default.
- W2164858045 countsByYear W21648580452021 @default.
- W2164858045 countsByYear W21648580452022 @default.
- W2164858045 countsByYear W21648580452023 @default.
- W2164858045 crossrefType "journal-article" @default.
- W2164858045 hasAuthorship W2164858045A5003335288 @default.
- W2164858045 hasAuthorship W2164858045A5005113837 @default.
- W2164858045 hasAuthorship W2164858045A5027269428 @default.
- W2164858045 hasAuthorship W2164858045A5029796262 @default.
- W2164858045 hasAuthorship W2164858045A5031531166 @default.
- W2164858045 hasAuthorship W2164858045A5035639364 @default.
- W2164858045 hasAuthorship W2164858045A5040449706 @default.
- W2164858045 hasAuthorship W2164858045A5053704561 @default.
- W2164858045 hasAuthorship W2164858045A5062789852 @default.
- W2164858045 hasAuthorship W2164858045A5064863811 @default.
- W2164858045 hasAuthorship W2164858045A5067393049 @default.
- W2164858045 hasAuthorship W2164858045A5071102167 @default.
- W2164858045 hasAuthorship W2164858045A5076851275 @default.
- W2164858045 hasAuthorship W2164858045A5080399165 @default.
- W2164858045 hasConcept C126322002 @default.
- W2164858045 hasConcept C141071460 @default.
- W2164858045 hasConcept C142724271 @default.
- W2164858045 hasConcept C168563851 @default.
- W2164858045 hasConcept C198451711 @default.
- W2164858045 hasConcept C204787440 @default.
- W2164858045 hasConcept C27081682 @default.
- W2164858045 hasConcept C2776233030 @default.
- W2164858045 hasConcept C2777077863 @default.
- W2164858045 hasConcept C2777575956 @default.
- W2164858045 hasConcept C2778886723 @default.
- W2164858045 hasConcept C2781059491 @default.
- W2164858045 hasConcept C71924100 @default.
- W2164858045 hasConcept C90924648 @default.
- W2164858045 hasConceptScore W2164858045C126322002 @default.
- W2164858045 hasConceptScore W2164858045C141071460 @default.
- W2164858045 hasConceptScore W2164858045C142724271 @default.
- W2164858045 hasConceptScore W2164858045C168563851 @default.
- W2164858045 hasConceptScore W2164858045C198451711 @default.
- W2164858045 hasConceptScore W2164858045C204787440 @default.
- W2164858045 hasConceptScore W2164858045C27081682 @default.
- W2164858045 hasConceptScore W2164858045C2776233030 @default.
- W2164858045 hasConceptScore W2164858045C2777077863 @default.
- W2164858045 hasConceptScore W2164858045C2777575956 @default.
- W2164858045 hasConceptScore W2164858045C2778886723 @default.
- W2164858045 hasConceptScore W2164858045C2781059491 @default.
- W2164858045 hasConceptScore W2164858045C71924100 @default.
- W2164858045 hasConceptScore W2164858045C90924648 @default.
- W2164858045 hasIssue "9865" @default.